Division of UnitedHealth Group Co.
Latest From OptumRx Inc.
Shares in Eylea-maker Regeneron slid after FDA approved Novartis's competing VEGF inhibitor for treating AMD, but some observers said investors had overreacted.
UnitedHealthcare’s pharmacy benefit manager highlights potential cost pressures from upcoming novel or improved treatments for diabetes, wet AMD, HIV and migraine, as well as luspatercept for beta thalassemia, in its latest pipeline report.
Annual large employer health benefits survey for 2020 and beyond finds support for government price negotiation and payment through a national fund. Plans to expand point-of-sale rebates and coupon accumulator programs also reported.
Recent mergers between PBMs and insurers should address one long-term strategic objective of pharma – the recognition by payors of the value of biopharmaceutical products in relation to other medical costs.
- Therapeutic Areas
- Prescription Solutions
- North America
- Parent & Subsidiaries
- UnitedHealth Group Co.
- Senior Management
Timothy Wicks, CEO
Jeffrey Grosklags, CFO
- Contact Info
Phone: (800) 788-4863
2300 Main St.
Irvine, CA 92614
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.